Description
Benefits
The Alere NMP22® BladderChek® Test offers a wide range of product benefits:
- Ability to test patients at risk for bladder cancer.
- Easy testing process, only requiring 4 drops of urine to run the test.
- Fast results in 30 minutes, allowing consultation during the same visit.
- An ideal adjunct marker to cystoscopy as found in one study:
- 99% sensitivity when combined with cystoscopy, giving greater confidence that recurrent cancer has been detected.1
- 99% NPV overall when combined with cystoscopy, the most effective diagnostic combination for ruling out bladder cancer.1,2
Specifications
The Alere NMP22® BladderChek® Test works by detecting nuclear matrix protein (NMP22) in the urine, which bladder cancer cells release at higher levels than normal cells.3 Even at the early stages of the disease, elevated levels of NMP22 can be detected using an NMP22-specific assay, making it an ideal marker for early diagnosis and monitoring in conjunction with standard diagnostic procedures.
References
1. Grossman et al., JAMA Jan 18, 2006 (overall NPV: 99.8% JAMA 2006 Surveillance Study +99.3% NMP JAMA 2005 Detection Study / 2 = 99,5%)
2. Grossman et al., JAMA Feb 16, 2005
3. Kumar, A., Kumar R., Gupta N. Biological Markers in the Diagnosis of Recurrent Bladder Cancer: Bladder Cancer Markers in Clinical Practice. Jpn. J. Clin. Oncol. 2006: 36(3) 172-175.
